HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.

AbstractPURPOSE:
To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients.
METHODS:
Patients with chemo-naïve, histologically confirmed AGC were eligible. S-1 was given orally at dose of 40, 50 or 60 mg, twice daily for patients with body surface <1.25, 1.25-1.5 and >1.5 m(2), respectively, on day 1-28 every 42 days/cycle.
RESULTS:
Thirty-four patients were included. On intent-to-treat analysis, the overall response rate, median progression-free and overall survival were 35.3% [95% confidence interval (CI): 19.2-51.3%], 2.9 (95% CI: 2.4-5.8) months and 9.8 (95% CI: 6.1-NA) months, respectively. The most common grade 3-4 toxicities were anemia 23.5% and neutropenia 11.8%. There were two treatment-related mortality, which occurred in patients with suboptimal renal function underestimated by serum creatinine level at study entry. Single-dose pharmacokinetic study showed trend toward lower AUC(5-FU), and higher AUC(FT) and AUC(Oxo) comparing to most Western reports.
CONCLUSIONS:
The efficacy, toxicity and pharmacokinetic profiles of S-1 in current study are compatible with those from other Asian populations. Accurate renal function assessment and more closely monitoring is mandatory for S-1 therapy in patients with low body mass. Literature review suggests that, besides AUC(5-FU), AUC(Oxo) may also attribute to the difference in the compliance to S-1 between Asian and Caucasian populations.
AuthorsJen-Shi Chen, Yee Chao, Ruey-Kuen Hsieh, Ann-Lii Cheng, Po-Min Chen, Tzeon-Jye Chiou, Tsu-Yi Chao, Kun-Huei Yeh, Li-Tzong Chen, Jacqueline Whang-Peng
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 67 Issue 6 Pg. 1281-9 (Jun 2011) ISSN: 1432-0843 [Electronic] Germany
PMID20714726 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Asian Continental Ancestry Group
  • Drug Combinations
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Oxonic Acid (adverse effects, pharmacokinetics, therapeutic use)
  • Stomach Neoplasms (drug therapy, pathology)
  • Taiwan
  • Tegafur (adverse effects, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: